Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 300

1.

Is Tamsulosin Linked to Dementia in the Elderly?

Frankel JK, Duan Y, Albertsen PC.

Curr Urol Rep. 2018 Jul 3;19(9):69. doi: 10.1007/s11934-018-0821-0. Review.

PMID:
29971698
2.

Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study.

Demir M, Akin Y, Terim KAK, Gulum M, Buyukfirat E, Ciftci H, Yeni E.

Int Braz J Urol. 2018 May-Jun;44(3):600-607. doi: 10.1590/S1677-5538.IBJU.2017.0668.

3.

Efficacy and safety of alpha blockers in medical expulsive therapy for ureteral stones: a mixed treatment network meta-analysis and trial sequential analysis of randomized controlled clinical trials.

Sridharan K, Sivaramakrishnan G.

Expert Rev Clin Pharmacol. 2018 Mar;11(3):291-307. doi: 10.1080/17512433.2018.1424537. Epub 2018 Jan 19. Review.

PMID:
29334287
4.

The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia.

Dogan M, Kutluksaman B, Keles I, Karalar M, Halat AO.

Curr Eye Res. 2017 Dec;42(12):1638-1643. doi: 10.1080/02713683.2017.1359306. Epub 2017 Sep 22.

PMID:
28937828
5.

Evaluation of Anterior Segment Changes of Patients Taking Alpha1-Blockers by Ultrasound Biomicroscopy in the Drug-free Period.

Acar Y, Eltutar K, Zırtıloğlu S.

Turk J Ophthalmol. 2017 Aug;47(4):186-191. doi: 10.4274/tjo.45336. Epub 2017 Aug 15.

6.

[How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4].

Bensalah N, Garcia S, Rose FX, Bedouch P, Conort O, Juste M, Roubille R, Allenet B, Tod M, Charpiat B.

Prog Urol. 2017 Apr;27(5):275-282. doi: 10.1016/j.purol.2017.02.003. Epub 2017 Mar 30. Review. French.

PMID:
28365198
7.

CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.

Kitaguchi T, Moriyama Y, Taniguchi T, Maeda S, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Miyamoto N.

J Pharmacol Toxicol Methods. 2017 May - Jun;85:73-81. doi: 10.1016/j.vascn.2017.02.001. Epub 2017 Feb 3.

PMID:
28163191
8.

The effect of alfuzosin on renal resistive index, urinary electrolytes and β2 microglobulin levels and TGF β-1 levels of kidney tissue in rats with unilateral ureteropelvic junction obstruction.

Kose F, Turkyilmaz Z, Sonmez K, Karabulut R, Poyraz A, Gulbahar O, Aral A, Damar C, Kaya C, Can Basaklar A.

Ren Fail. 2016 Sep;38(8):1283-90. doi: 10.1080/0886022X.2016.1207049. Epub 2016 Jul 12.

PMID:
27402370
9.

Risk factors for intraoperative floppy iris syndrome: a prospective study.

Chatziralli IP, Peponis V, Parikakis E, Maniatea A, Patsea E, Mitropoulos P; Medscape.

Eye (Lond). 2016 Aug;30(8):1039-44. doi: 10.1038/eye.2016.122. Epub 2016 Jul 1.

10.

Efficacy of α-blocker in improving ureteral stent-related symptoms: a meta-analysis of both direct and indirect comparison.

He F, Man LB, Li GZ, Liu N.

Drug Des Devel Ther. 2016 May 26;10:1783-93. doi: 10.2147/DDDT.S103195. eCollection 2016.

11.

Prophylactic effects of alpha-blockers, Tamsulosin and Alfuzosin, on postoperative urinary retention in male patients undergoing urologic surgery under spinal anaesthesia.

Akkoc A, Aydin C, Topaktas R, Kartalmis M, Altin S, Isen K, Metin A.

Int Braz J Urol. 2016 May-Jun;42(3):578-84. doi: 10.1590/S1677-5538.IBJU.2015.0256.

12.

Therapy of calcium oxalate urolithiasis in a rhesus macaque (Macaca mulatta).

Conze T, Wehrend A, Exner C, Kaminiarz A.

J Med Primatol. 2016 Aug;45(4):195-7. doi: 10.1111/jmp.12221. Epub 2016 Jun 10.

PMID:
27283130
13.

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.

Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK.

Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40. doi: 10.4103/0253-7613.178825.

14.

Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.

Forbes A, Anoopkumar-Dukie S, Chess-Williams R, McDermott C.

Prostate. 2016 Jun;76(8):757-66. doi: 10.1002/pros.23167. Epub 2016 Feb 16.

PMID:
26880388
15.

α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies.

Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, Longo N, Verze P, Creta M, Mirone V.

Eur Urol. 2016 Jun;69(6):1091-101. doi: 10.1016/j.eururo.2015.12.034. Epub 2016 Jan 28. Review.

PMID:
26831507
16.

Modified corneal incisions in intraoperative floppy iris syndrome (IFIS)-prone patients.

Armarnik S, Mimouni M, Rosen E, Assia EI, Segev F.

Graefes Arch Clin Exp Ophthalmol. 2016 Jan;254(1):123-7. doi: 10.1007/s00417-015-3188-7. Epub 2015 Nov 9.

PMID:
26553196
17.
18.

The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study.

Welk B, McArthur E, Fraser LA, Hayward J, Dixon S, Hwang YJ, Ordon M.

BMJ. 2015 Oct 26;351:h5398. doi: 10.1136/bmj.h5398.

19.

Temperature influencing permeation pattern of alfuzosin: an investigation using DoE.

Pattnaik S, Swain K, Rao JV, Varun T, Mallick S.

Medicina (Kaunas). 2015;51(4):253-61. doi: 10.1016/j.medici.2015.07.002. Epub 2015 Jul 30.

20.

Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.

Liu C, Zeng G, Kang R, Wu W, Li J, Chen K, Wan SP.

PLoS One. 2015 Aug 5;10(8):e0134589. doi: 10.1371/journal.pone.0134589. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center